Assignee
PHARMAESSENTIA CORP
TW·4 granted patents·10 pending applications·0 citations·filing 2006–2025
Top patents by PatentIndex Score
14 records- 0175US12343381B2Dosage regimen for pegylated interferonPHARMAESSENTIA CORP·Filed 2022·Granted Jul 1, 2025·0 cites·22 claims
- 0266US2023096991A1Method of using pegylated interferon-alphaPHARMAESSENTIA CORP·Filed 2022·Application pending·0 cites
- 0366US2025186552A1Dosage regimen for pegylated interferonPHARMAESSENTIA CORP·Filed 2025·Application pending·0 cites
- 0465US2025101484A1Method to increase drug substance yieldPHARMAESSENTIA CORP·Filed 2024·Application pending·0 cites
- 0562US2025195616A1Method of using pegylated interferon-alphaPHARMAESSENTIA CORP·Filed 2025·Application pending·0 cites
- 0660US2023057788A1Method of treating chronic myeloid leukemia using pegylated interferon and tyrosine kinase inhibitorPHARMAESSENTIA CORP·Filed 2022·Application pending·0 cites
- 0757US11559567B2Dosage regimen for pegylated interferonPHARMAESSENTIA CORP·Filed 2015·Granted Jan 24, 2023·0 cites·20 claims
- 0857US2022152156A1Method of using pegylated interferon-alphaPHARMAESSENTIA CORP·Filed 2021·Application pending·0 cites
- 0955US2022362343A1Method of reducing tet2 mutant allele burdenPHARMAESSENTIA CORP·Filed 2022·Application pending·0 cites
- 1048US2025269045A1Unique pegylated granulocyte colony stimulating factor, methods of use and preparation thereofPHARMAESSENTIA CORP·Filed 2025·Application pending·0 cites
- 1144US2011098451A1Peptide-polymer conjugatesPHARMAESSENTIA CORP·Filed 2010·Application pending·0 cites
- 1240US7485716B2Stereoselective synthesis of β-nucleosidesPHARMAESSENTIA CORP·Filed 2006·Granted Feb 3, 2009·0 cites·20 claims
- 1338US2007185135A1Drug-Polymer ConjugatesPHARMAESSENTIA CORP·Filed 2006·Application pending·0 cites
- 1436US8975393B2Synthesis of 5-deoxy-5′-fluorocytidine compoundsPHARMAESSENTIA CORP·Filed 2013·Granted Mar 10, 2015·0 cites·17 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →